# A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

> **NCT06039384** · PHASE1 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 6 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** INCB099280
- **DRUG:** adagrasib

## Key facts

- **NCT ID:** NCT06039384
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-12-28
- **Primary completion:** 2025-04-11
- **Final completion:** 2025-07-11
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** This was a strategic business decision. There were no safety concerns contributing to this decision.
- **Last updated:** 2025-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06039384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06039384, "A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06039384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*